Kiora Pharmaceuticals, Inc. (KPRX) DCF Valuation

Kiora Pharmaceuticals, Inc. (KPRX) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Kiora Pharmaceuticals, Inc. (KPRX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Optimize your time and improve precision with our (KPRX) DCF Calculator! Utilizing real data from Kiora Pharmaceuticals, Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and value Kiora Pharmaceuticals like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.7 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -99.55 -100 0 0 -49.89 -49.89 -49.89 -49.89 -49.89
EBITDA -6.8 -6.6 -13.7 -13.6 -12.4 .0 .0 .0 .0 .0
EBITDA, % -252.68 -55106.6 100 100 100 20 20 20 20 20
Depreciation .2 .2 .2 .1 .2 .0 .0 .0 .0 .0
Depreciation, % 7.96 1660.34 100 100 100 81.59 81.59 81.59 81.59 81.59
EBIT -7.0 -6.8 -14.0 -13.7 -12.6 .0 .0 .0 .0 .0
EBIT, % -260.65 -56766.95 100 100 100 20 20 20 20 20
Total Cash 3.8 1.2 7.9 6.0 2.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .1 .5 1.4 2.0
Account Receivables, % 0.18083 754.42 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 100 100 100 60 60 60 60 60
Accounts Payable .2 .4 .2 1.0 .2 .0 .0 .0 .0 .0
Accounts Payable, % 7.83 3605.3 100 100 100 81.57 81.57 81.57 81.57 81.57
Capital Expenditure .0 -.1 -.1 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 0 -1109.49 100 100 100 -20 -20 -20 -20 -20
Tax Rate, % -0.727 -0.727 -0.727 -0.727 -0.727 -0.727 -0.727 -0.727 -0.727 -0.727
EBITAT -7.1 -6.9 -13.7 -13.6 -12.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -6.7 -6.7 -14.3 -13.4 -13.9 1.8 .0 .0 .0 .0
WACC, % 5.68 5.68 5.67 5.68 5.68 5.68 5.68 5.68 5.68 5.68
PV UFCF
SUM PV UFCF 1.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 2
Net Debt -2
Equity Value 4
Diluted Shares Outstanding, MM 1
Equity Value Per Share 7.61

What You Will Get

  • Real Kiora Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Kiora Pharmaceuticals, Inc. (KPRX).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to KPRX.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Kiora’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for KPRX.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Kiora Pharmaceuticals, Inc. (KPRX).

Key Features

  • Customizable Research Inputs: Adjust essential metrics such as drug development timelines, market penetration rates, and R&D expenditures.
  • Instant Valuation Metrics: Computes intrinsic value, net present value (NPV), and other essential outputs in real-time.
  • High-Precision Analytics: Leverages Kiora Pharmaceuticals' actual financial data for accurate valuation results.
  • Streamlined Scenario Testing: Effortlessly evaluate various hypotheses and assess their impacts.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  • 1. Open the Template: Download and open the Excel file containing Kiora Pharmaceuticals, Inc.'s preloaded data.
  • 2. Edit Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures specific to KPRX.
  • 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV for Kiora Pharmaceuticals.
  • 4. Test Scenarios: Evaluate various forecasts to explore different valuation outcomes for KPRX.
  • 5. Use with Confidence: Present professional valuation insights related to Kiora Pharmaceuticals, Inc. to inform your decisions.

Why Choose This Calculator?

  • Designed for Industry Leaders: A sophisticated tool utilized by pharmaceutical analysts, investment managers, and healthcare consultants.
  • Comprehensive Data: Kiora Pharmaceuticals’ historical and projected financials preloaded for enhanced precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions to evaluate potential outcomes.
  • Insightful Results: Automatically computes intrinsic value, NPV, and essential financial metrics.
  • User-Friendly Interface: Step-by-step guidance ensures a seamless experience throughout the calculation process.

Who Should Use This Product?

  • Investors: Accurately estimate Kiora Pharmaceuticals’ fair value before making investment decisions.
  • CFOs: Leverage a professional-grade DCF model for financial reporting and analysis related to Kiora Pharmaceuticals (KPRX).
  • Consultants: Quickly adapt the template for valuation reports for clients focusing on Kiora Pharmaceuticals (KPRX).
  • Entrepreneurs: Gain insights into financial modeling used by leading pharmaceutical companies, including Kiora Pharmaceuticals (KPRX).
  • Educators: Use it as a teaching tool to demonstrate valuation methodologies relevant to the pharmaceutical industry.

What the Template Contains

  • Pre-Filled DCF Model: Kiora Pharmaceuticals’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Kiora Pharmaceuticals’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.